CIS43 and L9, two CSP monoclonal antibodies in clinical development for primary malaria prophylaxis, display cross reactivity with the major (NANP) repetitive motif of the central repeat region (immunodominant) and their primary target (immunoprotective) (14, 57). This evidence concerns the gene DNAJC5 and malaria.